Our clinical results showed that NSCLC patients with an increase in plasma CHI3L1 level were significantly associated with poor prognosis or therapeutic resistance to anti-PD-1/PD-L1 immunotherapy. Here, CHI3L1 is linked to non-small cell lung carcinoma.